IceCure MedicalICCM
About: Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Employees: 64
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 [Q2] → 15 (+1) [Q3]
0.37% less ownership
Funds ownership: 0.77% [Q2] → 0.39% (-0.37%) [Q3]
60% less capital invested
Capital invested by funds: $272K [Q2] → $109K (-$163K) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target | 123%upside $2.50 | Buy Reiterated | 27 Nov 2024 |
Financial journalist opinion
Based on 5 articles about ICCM published over the past 30 days